Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NECESSITY: New Clinical End-points in Primary Sjögren’s Syndrome
2023-510054-16-00Phase 2Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of leflunomide, mycophenolate mofetil and hydroxychloroquine in primary Sjögren's syndrome (8 cohorts), sponsored by Assistance publique - Hôpitaux de Paris. Planned start Feb 2024; status: authorised.
02
Drugs
leflunomidemycophenolate mofetilhydroxychloroquine
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on 2023-510054-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510054-16-00.